4. Oncology Biosimilars Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Oncology Biosimilars Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Technology Landscape
4.6.4. Legal Landscape
4.6.5. Social Landscape
5. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Monoclonal Antibodies
5.3.2. Granulocyte Colony-Stimulating Factor (G-CSF)
5.3.3. Pipeline Analysis
5.3.3.1. Phase III Drug Analysis
5.3.3.1.1. Rituximab Biosimilar
5.3.3.1.2. Trastuzumab Biosimilar
5.3.3.1.3. Filgrastim Biosimilar
5.3.3.1.4. Bevacizumab Biosimilar
5.3.3.2. Tabular Representation of Phase I and Phase II Drugs
6. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2024 Versus 2033
6.3. Market Segmentation
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Cervical Cancer
6.3.5. Blood Cancer
6.3.6. Neutropenia
6.3.7. Others (Brain Cancer, Stomach Cancer, etc.)
7. North America Oncology Biosimilars Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
7.3. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
7.4.Oncology Biosimilars Market: By Region, 2023-2033, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
7.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
7.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
7.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8. UK and European Union Oncology Biosimilars Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.3. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.Oncology Biosimilars Market: By Region, 2023-2033, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.4.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.1.5. France
8.4.1.5.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.5.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
8.4.1.6.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9. Asia Pacific Oncology Biosimilars Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.3. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.Oncology Biosimilars Market: By Region, 2023-2033, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.1.3. India
9.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.4.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.5.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
9.4.1.6.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
10. Latin America Oncology Biosimilars Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
10.3. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
10.4.Oncology Biosimilars Market: By Region, 2023-2033, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
10.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
10.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
10.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
11. Middle East and Africa Oncology Biosimilars Market, 2023-2033, USD (Million)
11.1. Market Overview
11.2. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
11.3. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
11.4.Oncology Biosimilars Market: By Region, 2023-2033, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
11.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
11.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2023-2033, USD (Million)
11.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2023-2033, USD (Million)
12. Company Profile
12.1. Amgen, Inc.
(Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Mylan N.V.
12.3. Samsung Bioepis Co. Ltd.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer, Inc.
12.6. Celltrion Healthcare
12.7. Novartis International AG
12.8. Biocon Limited
12.9. Biogen Idec
12.10. Sandoz
12.11. Dr. Reddy’s Laboratory
12.12. Merck & Co.
12.13. Shanghai Henlius Biotech, Inc.
12.14. Biocad
